NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer product candidates primarily for the treatment of various cancers; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NK
CUSIPN/A
Phone858-633-0300
Debt
Debt-to-Equity Ratio0.01
Current Ratio6.54
Quick Ratio6.54
Price-To-Earnings
Trailing P/E Ratio-2.74
Forward P/E Ratio-2.14
P/E GrowthN/A
Sales & Book Value
Annual Sales$50,000.00
Price / Sales5,138.32
Cash FlowN/A
Price / CashN/A
Book Value$2.75 per share
Price / Book1.20
Profitability
EPS (Most Recent Fiscal Year)($1.20)
Net Income$-96,420,000.00
Net Margins-254,917.94%
Return on Equity-43.71%
Return on Assets-37.53%
Miscellaneous
Employees139
Outstanding Shares78,090,000
Market Cap$267.06
Nantkwest (NASDAQ:NK) Frequently Asked Questions
What is Nantkwest's stock symbol?
Nantkwest trades on the NASDAQ under the ticker symbol "NK."
How were Nantkwest's earnings last quarter?
Nantkwest Inc (NASDAQ:NK) posted its quarterly earnings data on Monday, May, 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.01. The biotechnology company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. Nantkwest had a negative return on equity of 43.71% and a negative net margin of 254,917.94%. View Nantkwest's Earnings History.
What price target have analysts set for NK?
2 Wall Street analysts have issued twelve-month price objectives for Nantkwest's stock. Their predictions range from $3.00 to $3.00. On average, they anticipate Nantkwest's share price to reach $3.00 in the next year. This suggests that the stock has a possible downside of 8.8%. View Analyst Ratings for Nantkwest.
What is the consensus analysts' recommendation for Nantkwest?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
Who are some of Nantkwest's key competitors?
Some companies that are related to Nantkwest include Adaptimmune Therapeutics (ADAP), DBV Technologies (DBVT), BAVARIAN NORDIC/S (BVNRY), Autolus Therapeutics (AUTL), Heska (HSKA), La Jolla Pharmaceutical (LJPC), Avrobio (AVRO), Translate Bio (TBIO), Mesoblast (MESO), CASI Pharmaceuticals (CASI), BioCryst Pharmaceuticals (BCRX), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Nightstar Therapeutics (NITE) and Novavax (NVAX).
Who are Nantkwest's key executives?
Nantkwest's management team includes the folowing people:
- Dr. Patrick Soon-Shiong FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 65)
- Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 53)
- Mr. Richard J. Tajak, Consultant (Age 65)
- Ms. Sonja Nelson, Chief Financial Officer (Age 45)
- Mr. David J. Pyrce M.B.A., Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 61)
When did Nantkwest IPO?
(NK) raised $150 million in an initial public offering (IPO) on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.
Has Nantkwest been receiving favorable news coverage?
Headlines about NK stock have been trending somewhat positive on Saturday, Accern Sentiment reports. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nantkwest earned a media sentiment score of 0.11 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.11 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Nantkwest?
Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nantkwest's stock price today?
One share of NK stock can currently be purchased for approximately $3.29.
How big of a company is Nantkwest?
Nantkwest has a market capitalization of $267.06 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,420,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Nantkwest employs 139 workers across the globe.
How can I contact Nantkwest?
Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]
MarketBeat Community Rating for Nantkwest (NASDAQ NK)
MarketBeat's community ratings are surveys of what our community members think about Nantkwest and other stocks. Vote "Outperform" if you believe NK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days.
